Last reviewed · How we verify
Polyclonal anti-T-cell antibodies
Polyclonal anti-T-cell antibodies is a Small molecule drug developed by Institute for Clinical and Experimental Medicine. It is currently in Phase 1 development.
At a glance
| Generic name | Polyclonal anti-T-cell antibodies |
|---|---|
| Sponsor | Institute for Clinical and Experimental Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
- Precision Administration of Anti-thymocyte Globulin With or Without Verapamil (PHASE2)
- PETHEMA-BLIN-01/PET069014 (BLIN-01) (PHASE2)
- Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma (PHASE1, PHASE2)
- T&B Depletion Non Malignant (PHASE2)
- Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) (PHASE3)
- Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polyclonal anti-T-cell antibodies CI brief — competitive landscape report
- Polyclonal anti-T-cell antibodies updates RSS · CI watch RSS
- Institute for Clinical and Experimental Medicine portfolio CI
Frequently asked questions about Polyclonal anti-T-cell antibodies
What is Polyclonal anti-T-cell antibodies?
Polyclonal anti-T-cell antibodies is a Small molecule drug developed by Institute for Clinical and Experimental Medicine.
Who makes Polyclonal anti-T-cell antibodies?
Polyclonal anti-T-cell antibodies is developed by Institute for Clinical and Experimental Medicine (see full Institute for Clinical and Experimental Medicine pipeline at /company/institute-for-clinical-and-experimental-medicine).
What development phase is Polyclonal anti-T-cell antibodies in?
Polyclonal anti-T-cell antibodies is in Phase 1.